



ISSN : 2347 - 2243

Indo - American Journal of Life Sciences and Biotechnology



<https://iajlb.org>

Email : editor@iajlb.com or iajlb.editor@gmail.com



Isolation of Lytic Bacteriophages Against Multidrug-Resistant *Klebsiella pneumoniae* From Hospital Sewage

Eoin Brennan¹●, Guillaume Lemarchand²●, Annika Weidenfeld³●

¹Scientist, Department of Microbiology, Shannon Estuary Institute of Nursing and Health Sciences, Ennis, Ireland.

²Scientist, Department of Microbiology, Vosges Institute of Applied Microbiology, Epinal, France.

³Scientist, Department of Microbiology, Oberlausitz Centre for Molecular Medicine, Bautzen, Germany.

Email: ¹e.brennan@seinhs.ie, ²g.lemarchand@viam-e.fr, ³a.weidenfeld@ocmm.de

ORCID: ¹0000-0001-3673-9833, ²0000-0001-4573-6191, ³0000-0001-3200-3896

Received: February 22, 2018 Accepted: June 30, 2018 Published: October 13, 2018

DOI: [10.62644/iajlb.2018.v15.i4.pp1-8](https://doi.org/10.62644/iajlb.2018.v15.i4.pp1-8)

ABSTRACT

Klebsiella pneumoniae is a leading cause of hospital-acquired infection, and strains resistant to many antibiotic classes, including carbapenems, have narrowed the options available to clinicians. Lytic bacteriophages, the viruses that infect and burst bacteria, are being revisited as a complement to antibiotics, and hospital sewage is often proposed as a rich place to find them because it concentrates the bacteria they prey on. This narrative review asks what the published literature says about isolating lytic phages against multidrug-resistant *K. pneumoniae* from hospital sewage, how candidate phages are characterised, and how much weight the reported findings can carry. It draws on work on the organism and its resistance, on phage biology and enrichment methods, on animal and clinical experience with phage preparations, and on the ecology of hospital wastewater, and it reports no new laboratory or patient data. Isolation is technically straightforward, but narrow host range, capsule dependence, rapid emergence of bacterial resistance and incomplete characterisation limit what a single isolate can offer. Most supportive evidence comes from cell culture and animal models. The review sets out a practical appraisal framework and the gaps that future studies should close.

Keywords: Bacteriophage; *Klebsiella pneumoniae*; Multidrug resistance; Hospital sewage; Phage isolation; Phage therapy; Narrative review

Citation: Brennan, Lemarchand and Weidenfeld [2018]. Isolation of Lytic Bacteriophages Against Multidrug-Resistant *Klebsiella pneumoniae* From Hospital Sewage. *Indo-Am. J. Life Sci. Biotechnol.* 15(4):1-8. DOI: [10.62644/iajlb.2018.v15.i4.pp1-8](https://doi.org/10.62644/iajlb.2018.v15.i4.pp1-8)

Article Class: Narrative Review

1. Introduction

Klebsiella pneumoniae is a Gram-negative bacterium that lives harmlessly in some people and causes serious disease in others, particularly patients who are hospitalised, immunocompromised or fitted with devices (1, 2). It is a frequent

cause of pneumonia, urinary tract and bloodstream infection in hospitals, and strains that resist several antibiotic classes at once have spread widely (3, 4). Resistance to carbapenems, often regarded as drugs of last resort, is an especially troubling development (5, 6).



Against this background, bacteriophages have returned to the discussion. Phages are viruses that infect bacteria; the lytic kind replicate inside the host and burst it open, and they have been studied as antibacterial agents for about a century (7, 8). Hospital sewage looks like a promising hunting ground, because it carries large numbers of the bacteria that phages feed on, including resistant ones, and phages tend to be found wherever their hosts are abundant (9, 10). The practical question is how much a phage found this way can really offer.

The title describes a laboratory exercise, the isolation of lytic phages against multidrug-resistant *K. pneumoniae* from hospital sewage. We do not report one: no local sampling, isolates or patient data are presented. This is a narrative review of what the published literature says about doing this work and what is often left unsaid. The aim is a fair account of what has been shown and what has merely been repeated.

2. Literature Review

2.1 *Klebsiella pneumoniae* and Multidrug Resistance

The species is encapsulated, and its polysaccharide capsule helps it evade host defences and, as discussed below, strongly influences which phages can attach to it (1, 2). Multidrug resistance, meaning non-susceptibility to several antimicrobial categories (11), is largely carried on mobile elements, which allows enzymes that break down beta-lactam antibiotics to move between strains and species (12, 13). A few successful lineages have been identified by genome sequencing and account for much of the resistant disease seen in hospitals worldwide (3, 4). Table 1 gathers the features of the organism that matter for anyone hoping to isolate phages against it.

Table 1. Features of *K. pneumoniae* that bear on phage isolation.

Feature	Relevance to phages
Polysaccharide capsule	Often the first receptor; strongly shapes host range (14, 15)
Resistance genes	Plasmid-borne enzymes make strains MDR (12, 13)
Hospital persistence	Colonises patients and surfaces (1, 2)
Biofilm growth	Can shield cells from antibiotics and phages (16)
Prophages in the genome	May confer immunity or add risk (17)

Note: Qualitative summary of the cited literature; no frequencies are given because they differ by setting.

2.2 Hospital Sewage as a Source

Hospital effluent concentrates organisms from many patients along with antibiotic residues (18). Reviews of wastewater treatment describe it as a place where resistant bacteria and resistance genes can accumulate and be released to the environment (18, 19). Resistant *K. pneumoniae* has been detected in hospital treatment-plant effluent and sludge (20), and resistant enterobacteria occur in municipal sewage more broadly (21). Phages that prey on them should be present too, though no sample is guaranteed to hold a useful one.

2.3 Phage Biology Relevant to Isolation

A phage first attaches to a receptor on the bacterial surface, injects its genome, replicates, and in the lytic cycle releases new particles by lysing the cell. Environmental surveys show that phages are enormously abundant and that their numbers follow those of their hosts (9, 22). Many phages also encode enzymes that degrade the capsule, and for *Klebsiella* this is central, since a phage with a capsule depolymerase can strip away the barrier the bacterium uses to protect itself (14, 23). Which of these steps limits infection differs from one phage to the next.



2.4 Phage Therapy: What Has Been Tried

Enthusiasm for phage therapy has outrun evidence at several points (7, 24). Reviews discuss its advantages, which include host specificity and self-amplification at the site of infection, and its disadvantages, which include narrow host range, the need to match phage to isolate and the immunological fate of phage particles in the body (8, 25). Well-designed trials in humans are few; a controlled trial in chronic ear infection reported benefit with a phage preparation, while a randomised trial of coliphage preparations in children with diarrhoea did not show clear clinical gain (26, 27). A personalised cocktail was also used to treat a patient with a disseminated, resistant *Acinetobacter baumannii* infection, but one patient is not a trial (28).

3. Materials and Methods

3.1 Scope and Question

The review asks one question in two parts. How are lytic phages against multidrug-resistant *K. pneumoniae* usually isolated from hospital sewage and characterised, and how far do the published findings support their use as antibacterial agents? Neither part is hard to ask, but each is easy to answer loosely.

3.2 Literature Assembly

The review draws on peer-reviewed work on the organism, phage biology and isolation, animal and clinical experience, and hospital wastewater. We did not carry out a formal systematic search and we do not claim one. The synthesis is narrative, and the choice of sources reflects the authors' judgement. A consequence is that the review is a better guide to what a sound study should contain than to the exact performance of any reported phage, and it avoids quoting figures from individual papers that could not be checked against

the originals for this article.

3.3 Appraisal Framework

To judge a report of a new phage we used six questions about its host panel, receptor, resistance, combination use, evidence beyond culture and characterisation, listed in Table 3. They draw on methodological accounts of host range (29), of phage cocktails (30, 31) and of phage selection and preparation (32). Table 2 lists the isolation stages we considered and the pitfalls most often described for each. It is a habit worth keeping even when the outcome is expected.

Table 2. Stages of isolating a lytic phage from sewage and the usual pitfalls.

Stage	What is done	Pitfall
Sampling	Collect and clarify sewage (33)	Mixed, variable matrix
Enrichment	Grow with host strain overnight (10, 33)	Favours fast phages
Detection	Spot test, then double-layer plates (34)	False plaques
Purification	Repeated single-plaque picks (32)	Mixed stocks
Growth traits	Adsorption, latent period, burst size (35)	Medium-dependent
Safety check	Screen for lysogeny and toxins (36, 37)	Often skipped

Note: Stages follow standard published protocols; pitfalls reflect the cited methods literature.

4. Results

4.1 How Phages Are Isolated and Characterised

The standard route begins with a clarified sample that is enriched with one or more host strains, so that any phage able to infect them multiplies to detectable levels (10, 33). Clear zones on a bacterial lawn, first in a spot test and then on double-layer



agar plates, indicate lysis, and single plaques are picked and re-plated several times to obtain a clonal stock (32, 34). Figure 1 sketches this workflow. The choices made at enrichment decide which phages are found at all, since fast phages that infect the chosen host are favoured.




Figure 1. From sewage sample to characterised phage stock (schematic, not data).

Growth traits are then measured, usually attachment, latent period and burst size (35). These depend on the medium and host physiology, so they describe an experiment as much as a phage. Morphology under the electron microscope and genome sequencing are used to place the phage in a taxonomic group and to look for genes that argue against therapeutic use (17, 36). Such differences look small on a plate and matter a great deal in a patient.

4.2 Host Range and the Capsule

Host range is the property most often reported and most often over-read. Reports describe phages that infect only a small share of the strains offered to them, and the reasons lie partly in receptors and partly in bacterial defences (29, 38). In *K. pneumoniae* the capsule type is a major determinant: phages and their depolymerases characterised for particular capsular types act on those types and not on others (14, 15). Several lytic *Klebsiella* phages have been shown to differ in kinetics and in the strains they affect (39), so one cannot be swapped for another

untested. A phage described as broad may simply have been tested on a narrow panel. This is why the same phage can look broadly useful in one paper and narrow in the next. Read this way, a phage that fails against one strain has not failed against the species.

4.3 Resistance and Phage Cocktails

Bacteria are not passive. They can change or lose receptors, modify the capsule, or use intracellular defence systems to resist phage infection (38). In culture, regrowth after an initial fall in bacterial numbers is commonly seen and is usually attributed to resistant variants (Figure 2); the figure is a schematic of that pattern, not a plot of data. How quickly resistance arises depends on the phage, the host and the conditions, and a short experiment may miss it. A culture that has had time to respond behaves differently from one that has not.




Figure 2. Expected pattern of bacterial regrowth under phage pressure (schematic, not data).

One answer is to use several phages together. Combinations that target different receptors are expected to make the emergence of resistance less likely, and methods for assembling cocktails have been described (30, 31). A cocktail is not free of difficulty. Each component must be characterised and its interactions understood (32, 37).

4.4 Evidence Beyond the Plate

Animal studies provide the main support for phages against *K. pneumoniae*. Phage



treatment improved outcomes in mouse models of liver abscess and bacteraemia (40), of pneumonia caused by a multidrug-resistant strain (41) and of burn wound infection, where a cocktail was compared with a single phage (42). These studies are encouraging, and they are also limited. A protective effect in a mouse does not show that a patient would benefit. The point is not that a study is poor, only that its result travels less far than its abstract suggests.

Human evidence for *Klebsiella* specifically is thin, and the wider clinical literature rests largely on case reports and a handful of trials with other pathogens (8, 24). Figure 3 sketches the ladder of evidence a candidate must climb. Most sewage isolates will stop at the lowest rungs, which is expected. A phage that kills in a flask but cannot be produced to a standard is not yet a medicine.




Figure 3. Evidence ladder for phage candidates; step heights are not counts (schematic).

Put plainly, the literature supports only a cautious statement. Lytic phages against multidrug-resistant *K. pneumoniae* can be isolated from wastewater with standard methods, they can kill their hosts in culture and, for a few, in animals, and the capsule and the speed of bacterial resistance limit how widely one phage can be used. Whether any particular sewage isolate is suitable for patients is not something a plate can answer, and the best summary is that the approach is promising but

incompletely tested. Table 3 turns these cautions into questions a reader can put to any new report. That is a modest claim, but it is the one the literature will currently bear. A clinician reading a phage report wants to know one thing: would it work on the strains in my ward?

5. Discussion

5.1 Interpretation and Practical Reading

The central finding is a conditional one. Isolation of lytic phages from hospital sewage is feasible and is likely to yield plaques when a suitable host is used, but the value of any isolate depends on its host range, receptor, stability of activity under resistance pressure and the safety of its genome. That fits the broader view that phage therapy needs matched, characterised and quality-controlled preparations instead of single, convenient isolates (8, 32). Nothing here argues against looking for phages; it argues for looking at them properly.

Table 3. Questions for appraising a report of a new anti-*Klebsiella* phage.

Question	Why it matters
How many strains were tested?	Host range rests on the panel (29)
Is the capsule type known?	Predicts reach across strains (15, 23)
Was resistance followed?	Regrowth can follow lysis (38)
Was a cocktail considered?	May delay resistance (30, 31)
Any animal or clinical data?	Culture lysis may not transfer (40, 41, 42)
Was the stock characterised?	Purity and safety bear on use (32, 37)

Note: Criteria drawn from the cited therapy and methods literature; they are not a validated scoring tool.

A second conditional concerns timing. Resistant *Klebsiella* is a pressing clinical problem and the literature on antibiotic development shows how few new agents



are arriving (43, 44). That urgency should not shorten the route from plate to patient, and a phage moved to use before its genome has been checked could set the field back. These cautions apply to any new antibacterial approach, not only to phages.

5.2 Limitations

This is a narrative review and shares the weaknesses of that form. Source selection reflects judgement, no formal search or scoring was done, and numerical results from individual studies are not quoted because they could not be checked against the primary reports. Evidence from other bacteria and from animal models is an imperfect proxy for human infection. Reviews are more useful when they say where the evidence stops than when they smooth it over.

5.3 Future Work

6. Conclusion

Hospital sewage can yield lytic phages against multidrug-resistant *K. pneumoniae*, and the methods for finding them are well established. What the literature does not yet show is that a given isolate will be useful in patients. Host range is narrow and tied to the capsule, bacteria can become resistant quickly, and the evidence beyond culture comes mainly from animal models. Researchers who isolate new phages will serve the field best by reporting how many strains they tested, how they checked safety and what happened to resistance over time.

7. Acknowledgements

The authors thank colleagues who commented on earlier drafts of this review.

8. Funding

This work received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

9. Conflict of Interest

The authors declare no conflict of interest.

10. Author Contributions

E.B. conceived the review and wrote the sections on phage isolation and characterisation. G.L. wrote the sections on *Klebsiella* and antimicrobial resistance. A.W. wrote the sections on phage therapy evidence and appraisal. All authors revised the manuscript and approved the final version.

11. Ethics Statement

This is a review of published literature. No human participants or animals were used and no ethical approval was required.

12. Data Availability

No new data were generated. All sources are cited in the reference list.

13. References

1. Podschun, R., & Ullmann, U. (1998). *Klebsiella* spp. as nosocomial pathogens: Epidemiology, taxonomy, typing methods, and pathogenicity factors. *Clinical Microbiology Reviews*, 11(4), 589–603. DOI: [10.1128/CMR.11.4.589](https://doi.org/10.1128/CMR.11.4.589)
2. Paczosa, M. K., & Mecsas, J. (2016). *Klebsiella pneumoniae*: Going on the offense with a strong defense. *Microbiology and Molecular Biology Reviews*, 80(3), 629–661. DOI: [10.1128/MMBR.00078-15](https://doi.org/10.1128/MMBR.00078-15)
3. Navon-Venezia, S., Kondratyeva, K., & Carattoli, A. (2017). *Klebsiella pneumoniae*: A major worldwide source and shuttle for antibiotic resistance. *FEMS Microbiology Reviews*, 41(3), 252–275. DOI: [10.1093/femsre/fux013](https://doi.org/10.1093/femsre/fux013)
4. Wyres, K. L., & Holt, K. E. (2016). *Klebsiella pneumoniae* population genomics and antimicrobial-resistant clones. *Trends in Microbiology*, 24(12), 944–956. DOI: [10.1016/j.tim.2016.09.007](https://doi.org/10.1016/j.tim.2016.09.007)
5. Nordmann, P., Cuzon, G., & Naas, T. (2009). The real threat of *Klebsiella pneumoniae* carbapenemase-producing bacteria. *The Lancet Infectious Diseases*, 9(4), 228–236. DOI: [10.1016/S1473-3099\(09\)70054-4](https://doi.org/10.1016/S1473-3099(09)70054-4)
6. Munoz-Price, L. S., Poirel, L., Bonomo, R. A., Schwaber, M. J., Daikos, G. L., Cormican, M., ... Quinn, J. P. (2013). Clinical epidemiology of the global expansion of *Klebsiella pneumoniae* carbapenemases. *The Lancet Infectious Diseases*,



- 13(9), 785–796. DOI: [10.1016/S1473-3099\(13\)70190-7](https://doi.org/10.1016/S1473-3099(13)70190-7)
7. Sulakvelidze, A., Alavidze, Z., & Morris, J. G. (2001). Bacteriophage therapy. *Antimicrobial Agents and Chemotherapy*, 45(3), 649–659. DOI: [10.1128/AAC.45.3.649-659.2001](https://doi.org/10.1128/AAC.45.3.649-659.2001)
 8. Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., & Abedon, S. T. (2010). Phage therapy in clinical practice: Treatment of human infections. *Current Pharmaceutical Biotechnology*, 11(1), 69–86. DOI: [10.2174/138920110790725401](https://doi.org/10.2174/138920110790725401)
 9. Weinbauer, M. G. (2004). Ecology of prokaryotic viruses. *FEMS Microbiology Reviews*, 28(2), 127–181. DOI: [10.1016/j.femsre.2003.08.001](https://doi.org/10.1016/j.femsre.2003.08.001)
 10. Clokie, M. R. J., Millard, A. D., Letarov, A. V., & Heaphy, S. (2011). Phages in nature. *Bacteriophage*, 1(1), 31–45. DOI: [10.4161/bact.1.1.14942](https://doi.org/10.4161/bact.1.1.14942)
 11. Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., ... Monnet, D. L. (2012). Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. *Clinical Microbiology and Infection*, 18(3), 268–281. DOI: [10.1111/j.1469-0691.2011.03570.x](https://doi.org/10.1111/j.1469-0691.2011.03570.x)
 12. Bush, K., & Jacoby, G. A. (2010). Updated functional classification of beta-lactamases. *Antimicrobial Agents and Chemotherapy*, 54(3), 969–976. DOI: [10.1128/AAC.01009-09](https://doi.org/10.1128/AAC.01009-09)
 13. Pitout, J. D. D., Nordmann, P., & Poirel, L. (2015). Carbapenemase-producing *Klebsiella pneumoniae*, a key pathogen set for global nosocomial dominance. *Antimicrobial Agents and Chemotherapy*, 59(10), 5873–5884. DOI: [10.1128/AAC.01019-15](https://doi.org/10.1128/AAC.01019-15)
 14. Hsu, C.-R., Lin, T.-L., Pan, Y.-J., Hsieh, P.-F., & Wang, J.-T. (2013). Isolation of a bacteriophage specific for a new capsular type of *Klebsiella pneumoniae* and characterization of its polysaccharide depolymerase. *PLoS ONE*, 8(8), e70092. DOI: [10.1371/journal.pone.0070092](https://doi.org/10.1371/journal.pone.0070092)
 15. Lin, T.-L., Hsieh, P.-F., Huang, Y.-T., Lee, W.-C., Tsai, Y.-T., Su, P.-A., ... Wang, J.-T. (2014). Isolation of a bacteriophage and its depolymerase specific for K1 capsule of *Klebsiella pneumoniae*: Implication in typing and treatment. *The Journal of Infectious Diseases*, 210(11), 1734–1744. DOI: [10.1093/infdis/jiu332](https://doi.org/10.1093/infdis/jiu332)
 16. Donlan, R. M., & Costerton, J. W. (2002). Biofilms: Survival mechanisms of clinically relevant microorganisms. *Clinical Microbiology Reviews*, 15(2), 167–193. DOI: [10.1128/CMR.15.2.167-193.2002](https://doi.org/10.1128/CMR.15.2.167-193.2002)
 17. Casjens, S. (2003). Prophages and bacterial genomics: What have we learned so far? *Molecular Microbiology*, 49(2), 277–300. DOI: [10.1046/j.1365-2958.2003.03580.x](https://doi.org/10.1046/j.1365-2958.2003.03580.x)
 18. Kümmerer, K. (2009). Antibiotics in the aquatic environment – A review – Part I. *Chemosphere*, 75(4), 417–434. DOI: [10.1016/j.chemosphere.2008.11.086](https://doi.org/10.1016/j.chemosphere.2008.11.086)
 19. Rizzo, L., Manaia, C., Merlin, C., Schwartz, T., Dagot, C., Ploy, M. C., ... Fatta-Kassinos, D. (2013). Urban wastewater treatment plants as hotspots for antibiotic resistant bacteria and genes spread into the environment: A review. *Science of the Total Environment*, 447, 345–360. DOI: [10.1016/j.scitotenv.2013.01.032](https://doi.org/10.1016/j.scitotenv.2013.01.032)
 20. Prado, T., Pereira, W. C., Silva, D. M., Seki, L. M., Carvalho, A. P., & Asensi, M. D. (2008). Detection of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* in effluents and sludge of a hospital sewage treatment plant. *Letters in Applied Microbiology*, 46(1), 136–141. DOI: [10.1111/j.1472-765X.2007.02272.x](https://doi.org/10.1111/j.1472-765X.2007.02272.x)
 21. Korzeniewska, E., & Harnisz, M. (2013). Extended-spectrum beta-lactamase (ESBL)-positive Enterobacteriaceae in municipal sewage and their emission to the environment. *Journal of Environmental Management*, 128, 904–911. DOI: [10.1016/j.jenvman.2013.06.051](https://doi.org/10.1016/j.jenvman.2013.06.051)
 22. Chibani-Chennoufi, S., Bruttin, A., Dillmann, M.-L., & Brüßow, H. (2004). Phage-host interaction: An ecological perspective. *Journal of Bacteriology*, 186(12), 3677–3686. DOI: [10.1128/JB.186.12.3677-3686.2004](https://doi.org/10.1128/JB.186.12.3677-3686.2004)
 23. Latka, A., Maciejewska, B., Majkowska-Skropek, G., Briers, Y., & Drulis-Kawa, Z. (2017). Bacteriophage-encoded virion-associated enzymes to overcome the carbohydrate barriers during the infection process. *Applied Microbiology and Biotechnology*, 101(8), 3103–3119. DOI: [10.1007/s00253-017-8224-6](https://doi.org/10.1007/s00253-017-8224-6)
 24. Abedon, S. T., Kuhl, S. J., Blasdel, B. G., & Kutter, E. M. (2011). Phage treatment of human infections. *Bacteriophage*, 1(2), 66–85. DOI: [10.4161/bact.1.2.15845](https://doi.org/10.4161/bact.1.2.15845)
 25. Loc-Carrillo, C., & Abedon, S. T. (2011). Pros and cons of phage therapy. *Bacteriophage*, 1(2), 111–114. DOI: [10.4161/bact.1.2.14590](https://doi.org/10.4161/bact.1.2.14590)
 26. Wright, A., Hawkins, C. H., Änggård, E. E., & Harper, D. R. (2009). A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant *Pseudomonas aeruginosa*; a preliminary report of efficacy. *Clinical Otolaryngology*, 34(4), 349–357. DOI: [10.1111/j.1749-4486.2009.01973.x](https://doi.org/10.1111/j.1749-4486.2009.01973.x)
 27. Sarker, S. A., Sultana, S., Reuteler, G., Moine, D., Descombes, P., Charton, F., ... Brüßow, H. (2016). Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: A randomized trial in children from Bangladesh.



- EBioMedicine*, 4, 124–137. DOI: [10.1016/j.ebiom.2015.12.023](https://doi.org/10.1016/j.ebiom.2015.12.023)
28. Schooley, R. T., Biswas, B., Gill, J. J., Hernandez-Morales, A., Lancaster, J., Lessor, L., ... Hamilton, T. (2017). Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant *Acinetobacter baumannii* infection. *Antimicrobial Agents and Chemotherapy*, 61(10), e00954-17. DOI: [10.1128/AAC.00954-17](https://doi.org/10.1128/AAC.00954-17)
 29. Hyman, P., & Abedon, S. T. (2010). Bacteriophage host range and bacterial resistance. *Advances in Applied Microbiology*, 70, 217–248. DOI: [10.1016/S0065-2164\(10\)70007-1](https://doi.org/10.1016/S0065-2164(10)70007-1)
 30. Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2013). Phage cocktails and the future of phage therapy. *Future Microbiology*, 8(6), 769–783. DOI: [10.2217/fmb.13.47](https://doi.org/10.2217/fmb.13.47)
 31. Gu, J., Liu, X., Li, Y., Han, W., Lei, L., Yang, Y., ... Feng, X. (2012). A method for generation phage cocktail with great therapeutic potential. *PLoS ONE*, 7(3), e31698. DOI: [10.1371/journal.pone.0031698](https://doi.org/10.1371/journal.pone.0031698)
 32. Gill, J. J., & Hyman, P. (2010). Phage choice, isolation, and preparation for phage therapy. *Current Pharmaceutical Biotechnology*, 11(1), 2–14. DOI: [10.2174/1389201110790725311](https://doi.org/10.2174/1389201110790725311)
 33. Van Twest, R., & Kropinski, A. M. (2009). Bacteriophage enrichment from water and soil. *Methods in Molecular Biology*, 501, 15–21. DOI: [10.1007/978-1-60327-164-6_2](https://doi.org/10.1007/978-1-60327-164-6_2)
 34. Kropinski, A. M., Mazzocco, A., Waddell, T. E., Lingohr, E., & Johnson, R. P. (2009). Enumeration of bacteriophages by double agar overlay plaque assay. *Methods in Molecular Biology*, 501, 69–76. DOI: [10.1007/978-1-60327-164-6_7](https://doi.org/10.1007/978-1-60327-164-6_7)
 35. Hyman, P., & Abedon, S. T. (2009). Practical methods for determining phage growth parameters. *Methods in Molecular Biology*, 501, 175–202. DOI: [10.1007/978-1-60327-164-6_18](https://doi.org/10.1007/978-1-60327-164-6_18)
 36. Hobbs, Z., & Abedon, S. T. (2016). Diversity of phage infection types and associated terminology: The problem with “lytic or lysogenic”. *FEMS Microbiology Letters*, 363(7), fnw047. DOI: [10.1093/femsle/fnw047](https://doi.org/10.1093/femsle/fnw047)
 37. Merabishvili, M., Pirnay, J.-P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., ... Vaneechoutte, M. (2009). Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. *PLoS ONE*, 4(3), e4944. DOI: [10.1371/journal.pone.0004944](https://doi.org/10.1371/journal.pone.0004944)
 38. Labrie, S. J., Samson, J. E., & Moineau, S. (2010). Bacteriophage resistance mechanisms. *Nature Reviews Microbiology*, 8(5), 317–327. DOI: [10.1038/nrmicro2315](https://doi.org/10.1038/nrmicro2315)
 39. Kęsik-Szeloch, A., Drulis-Kawa, Z., Weber-Dąbrowska, B., Kassner, J., Majkowska-Skrobek, G., Augustyniak, D., ... Kropinski, A. M. (2013). Characterising the biology of novel lytic bacteriophages infecting multidrug resistant *Klebsiella pneumoniae*. *Virology Journal*, 10, 100. DOI: [10.1186/1743-422X-10-100](https://doi.org/10.1186/1743-422X-10-100)
 40. Hung, C.-H., Kuo, C.-F., Wang, C.-H., Wu, C.-M., & Tsao, N. (2011). Experimental phage therapy in treating *Klebsiella pneumoniae*-mediated liver abscesses and bacteremia in mice. *Antimicrobial Agents and Chemotherapy*, 55(4), 1358–1365. DOI: [10.1128/AAC.01123-10](https://doi.org/10.1128/AAC.01123-10)
 41. Cao, F., Wang, X., Wang, L., Li, Z., Che, J., Wang, L., ... Tong, Y. (2015). Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistance *Klebsiella pneumoniae* in mice. *BioMed Research International*, 2015, 752930. DOI: [10.1155/2015/752930](https://doi.org/10.1155/2015/752930)
 42. Chadha, P., Katare, O. P., & Chhibber, S. (2016). In vivo efficacy of single phage versus phage cocktail in resolving burn wound infection in BALB/c mice. *Microbial Pathogenesis*, 99, 68–77. DOI: [10.1016/j.micpath.2016.08.001](https://doi.org/10.1016/j.micpath.2016.08.001)
 43. Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., ... Bartlett, J. (2009). Bad bugs, no drugs: No ESCAPE! An update from the Infectious Diseases Society of America. *Clinical Infectious Diseases*, 48(1), 1–12. DOI: [10.1086/595011](https://doi.org/10.1086/595011)
 44. Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., ... Zorzet, A. (2018). Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. *The Lancet Infectious Diseases*, 18(3), 318–327. DOI: [10.1016/S1473-3099\(17\)30753-3](https://doi.org/10.1016/S1473-3099(17)30753-3)